High‐dose vs low‐dose colchicine
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
Findings
What do systematic reviews say?
7 questions · 7 findings · 6 reviews
No studies found 1 · 14.3%GRADE not reported 2 · 28.6%Very low 2 · 28.6%Low 0 · 0%Moderate 1 · 14.3%High 1 · 14.3%
High‐concentration (8%) capsaicin patch vs control patch (0.4%)
Withdrawals due to adverse events · adults with postherpetic neuralgia
1 finding from 1 review
- Topical capsaicin (high concentration) for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes onlyno estimate extracted8 studies · 2487 participantsModerate
High‐dose colchicine vs placebo
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 111 participantsGRADE not reported
High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
- RR 0.89 [0.06, 13.08]3 studies · 104 participantsVery low
Intermittent/cyclic etidronate 400 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 1.09 [0.54, 2.18]Studies not reportedVery low
Risedronate 5 mg/day vs placebo
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.98 [0.9, 1.07]Studies not reportedHigh
Intervention not reported
Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
- High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found